

Clinical Oncology

Group leader

Barnadas Molins, Agusti (FGS)

Researchers

Anguera Palacios, Georgia (FGS)
 Arqueros Nuñez, Cristina (FGS)
 Barba Joaquin, Andrés (FGS)
 Boronat Ruiz, Laia (FGS)
 Calvo Verges, Nuria (FGS)
 Cerda Serda, Paula (FGS)
 Escuin Borrás, Daniel (IR)
 Gallego Rubio, Oscar Salvador (FGS)
 Juan Linares, Eva (FGS)
 López Pousa, Antonio (FGS)
 Majem Tarruella, Margarita (FGS)
 Maroto Rey, Jose Pablo (FGS)
 Paez López-Bravo, David (FGS)
 Ramon Y Cajal Asensio, Teresa (FGS)
 Salazar Blanco, Juliana (IR)
 Sebío García, Ana (FGS)
 Sullivan, Ivana Gabriela (FGS)
 Teres Lleida, Raul (FGS)
 Tibau Martorell, Ariadna (FGS)
 Virgili Manrique, Anna Cristina (FGS)

Research Technicians

Alfonso Ruiz, Rosa (IR)
 Andrés Nieto, Marta (IR)
 Bell Ramirez, Olga Lidia (IR)
 Calero Perez, Maria Del Pilar (IR)
 Castells Tello, Diana (IR)
 Di Giovanni Nuñez, Susana (IR)
 García Belinchon, Merce (IR)
 Gisbert Beamud, Alexandra (IR)
 Gonzalez Gomez, Luis (IR)
 Gonzalez Guerrero, Laura (IR)
 Hernandez García, Ricardo (IR)
 Lavernia Rosell, Laia (IR)
 Layana Antepará, Michelle Elizabeth (IR)
 Llobet Busquets, Mireia (IR)
 López Sanmartin, Consuelo (FGS)
 Menéndez Cuervo, Dulce Maria (IR)
 Molina Bayona, Silvia (IR)
 Moreno Gomez, Laura (IR)
 Perez Gorrini, Tiziana Giselle (IR)
 Ramirez García, Ona (IR)
 Reyes Vilasalo, Judith (IR)
 Ribas Bellavista, Laia (IR)
 Ribas Carbonell, Romina (IR)
 Roca Sola, Marc (IR)
 Salles Niubo, Mireia (IR)
 Serra López, Jorgina (FGS)
 Sola Vazquez, Eduard (IR)
 Tortosa Gallego, Belen (IR)
 Tricas Albareda, Andrea (IR)
 Vall Montero, Gaudi (IR)
 Van Veen Romero, Erika (IR)



DESCRIPTION

Clinical research: development of new therapeutic strategies; evaluation of the effectiveness of target treatments; detection of residual disease; design of clinical trials; development of phase I clinical trials; improvement of patient and their family's quality of life.

Translational research: design of personalized therapy studies; evaluation of prognostic and predictive molecular markers of response to treatment; molecular mechanisms of action and resistance to drugs; pharmacogenetics of cancer. We aim to translate this knowledge to (1) predict those patients with a higher risk of recurrence, (2) select patients more likely to benefit from specific treatments based on their tumor molecular characteristics and (3) assess the risk of toxicity of treatments according to the genetic characteristics of patients.

MAIN LINES OF RESEARCH

- Breast Tumors: Dr. Barnadas, Dra. Ramón y Cajal, Dra. Tibau, Dra. Arqueros, Dra. Andrés, Dra. Boronat and Dr. Escuin.
- Lung Tumors and melanomas: Dra. Majem, Dra. Sullivan, Dr. Barba, Jorgina Serra.
- Neuroendocrine Tumors: Dra. Sullivan, Dr. Paez.
- Head and Neck Tumors and central nervous system tumors: Dr. Gallego, Dra. Sebío.
- Hereditary and familial cancer: Dra. Ramón y Cajal, Dr. N Calvo.
- Digestive Tumors: Dr. Páez, Dra. Sebío, Dra. Virgili, Dr. Pelegrin, Dra. Martin Cullell, Dra. Cerda.



05.1.2 Oncohematologic Diseases Area

- Urologic Tumors: Dr. Maroto, Dra. Anguera.
- Sarcomas Unit: Dra. Sebio, Dra. Virgili, Dr. Terés, Dr. López Pousa.
- Laboratory of Translational Oncology: Dr. Escuin.

SCIENTIFIC CHALLENGES

- Identification of tumor molecular alterations and their clinical evolutionary course. Identification of these alterations would allow the use of specific targets and improvement of clinical responses. Currently, this is only possible for some neoplasms, and targeted therapies are administered to patients with advanced disease, for whom acceptable results are expected in terms of survival and tolerance. In recent years, we have implemented the use of next-generation sequencing cancer panels in certain tumors (lung, sarcomas, melanoma, colon, etc.) to identify patients eligible to specific target treatments. Our challenge is to expand this strategy to other carcinomas and to incorporate bioinformatics in the clinical practice to extract the maximum benefit from the information obtained to advance towards Precision Oncology.
- Response to treatment is short in certain cancers due to the heterogeneity of the tumors and the development of tumor clones that are resistant to the initial treatment. Therefore, it is essential to accurately identify the initial genetic alterations and those that develop secondarily to the treatment, to identify the mechanisms of resistance to systemic therapy and define therapeutic strategies based on this information.
- The use of liquid biopsy would allow the identification of molecular alterations at early stages of the disease, to evaluate the tumor load, and to monitor responses to systemic treatment. Our challenge is to set up a prospective sample collection strategy in patients with a high-risk of relapse to assess and monitor the effectiveness of therapies.
- To determine the immunological response of cancer patients, to identify treatments that potentiate the response in the tumor cells, and to define strategies to monitor those effects.

ACTIVE GRANTS

- Escuin Borrás, Daniel. Investigación del papel de los miRNAs y snoRNAs circulantes como marcadores surrogados del estatus de los ganglios

linfáticos en pacientes con cáncer de mama. PI19/00362. Instituto de Salud Carlos III (ISCIII). Duration: 2020-2023. 131.890,00 €.

- Paez López-Bravo, David. Integración de la farmacogenética y la telemedicina mediante salud móvil para el manejo de los efectos adversos en pacientes con cáncer colorrectal (ePGx study). PI21/01913. Instituto de Salud Carlos III (ISCIII). Duration: 2022-2024. 63.525,00 €.
- Serra López, Jorgina. PR-405/2020. Fundació Infermeria i Societat. Duration: 2021-2023. 4.290,00 €.

GRANTS AWARDED

- Barnadas Molins, Agustí. Recerca Clínica en Oncologia. 2021 SGR 00827. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Duration: 2022-2025. 36.000 €.
- Tibau Martorell, Ariadna. Beneficio clínico, precio y acceso de los nuevos medicamentos contra el cáncer en España y en el resto de Europa: un análisis internacional. PI23/00742. Instituto de Salud Carlos III. Duration: 2024-2026. 37.500 €.

SCIENTIFIC PRODUCTION

- Ahn MJ, Cho BC, Felipe E, Korantzis I, Ohashi K, Majem M, Juan O, Handzhiev S, Izumi H, Lee JS, Dziadziszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans A, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang TY, Martinez P, Anderson ES, Paz L, DeLLphi I. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. *NEW ENGLAND JOURNAL OF MEDICINE*. 2023; DOI:10.1056/NEJMoa2307980. PMID:37861218. IF:158,500 (Q1/1D). Document type: Article.
- Annesi I, Cecchi L, Biagioni B, Chung KF, Clot B, Coen MC, Amato GD, Damialis A, Dominguez J, Galan C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Papadopoulos NG, Quirce S, Sastre J, Tummon F, Traidl C, Walusiak J, Alonso P, Canelo C, Cantero Y, Rigau D, Salazar J, Verdugo F, Jutel M, Akdis CA, Agache I. Is exposure to pollen a risk factor for moderate and severe asthma exacerbations?. *ALLERGY*. 2023; 78(8)DOI:10.1111/all.15724. PMID:36961370. IF:12,400 (Q1/1D). Document type: Review.



05.1.2 Oncohematologic Diseases Area

- Arqueros C, Salazar J, Gallardo A, Andrés M, Tibau A, Bell OL, Artigas A, Lasa A, Cajal T, Lerma E, Barnadas A. Secreted Protein Acidic and Rich in Cysteine (<i>SPARC</i>) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients. *Biomedicines*. 2023; 11(12):3231. DOI:10.3390/biomedicines11123231. PMID:38137452. IF:4,700 (Q1/3D). Document type: Article.
- Bertran J, Giménez A, Román R, Talbot S, Whiteley R, Floc'h N, Martínez E, Martin MJ, Smith PD, Sullivan I, Terp MG, Saeh J, Marino C, Fabbri G, Guo G, Xu M, Tornador C, Aguilar A, Reguart N, Ditzel HJ, Martínez A, Nabau N, Gascó A, Rosell R, Pease JE, Polanska UM, Travers J, Urošević J, Molina MA. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AUR-KB or TTK inhibitors. *Molecular Cancer*. 2023; 22(1):110. DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:37,300 (Q1/1D). Document type: Article.
- Blakely CM, Weder W, Bubendorf L, He J, Majem M, Shyr Y, Chaft JE. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. *LUNG CANCER*. 2023; 177DOI:10.1016/j.lungcan.2023.01.002. PMID:36736076. IF:5,300 (Q2/3D). Document type: Review.
- Blanco R, Dómine M, González JL, Loutfi S, Alfaro J, Saldaña J, Rubio J, Campos B, Hidalgo J, Barba A, Márquez D, Martin M, Olaverri A, Nadal E. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. *LUNG CANCER*. 2023; 183:107318. DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:5,300 (Q2/3D). Document type: Article.
- Bracchiglione J, Rodríguez G, Requeijo C, Santero M, Salazar J, Salas K, Meade A-G, Antequera A, Auladell A, Quintana MJ, Solà I, Urrútia G, Acosta R, Bonfill X. Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers: An Overview of Systematic Reviews. *Cancers*. 2023; 15(3):766. DOI:10.3390/cancers15030766. PMID:36765723. IF:5,200 (Q2/3D). Document type: Review.
- Campos F, Téres R, Sebio A, Bettim BB, Martinez J. Survival Differences of Patients with Resected Extraskelatal Osteosarcoma Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review and Meta-analysis. *CLINICAL ONCOLOGY*. 2023; 35(12)DOI:10.1016/j.clon.2023.09.009. PMID:37777356. IF:3,400 (Q3/6D). Document type: Article.
- Canto E, Anguera G, Jimenez N, Mellado B, Ramirez O, Mariscal A, Maroto P, Vidal S. Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment. *Diagnostics*. 2023; 13(13):2222. DOI:10.3390/diagnostics13132222. PMID:37443615. IF:3,600 (Q2/4D). Document type: Article.
- Carmona E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Epidermolysis bullosa acquisita induced by atezolizumab. *JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT*. 2023; DOI:10.1111/ddg.15203. PMID:37658659. IF:3,600 (Q1/3D). Document type: Letter.
- Casanovas A, Sebio R, Ciendones M, Cuartero J, Estanyol B, Padrós J, García B, Barnadas A, Masia J. Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOptimize): A Protocol for a Randomized Controlled Trial. *PHYSICAL THERAPY*. 2023; 103(9):pzad062. DOI:10.1093/ptj/pzad062. PMID:37318267. IF:3,200 (Q1/3D). Document type: Article.
- Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. *Nature Communications*. 2023; 14(1):1070. DOI:10.1038/s41467-023-35961-y. PMID:36849494. IF:16,600 (Q1/1D). Document type: Article.
- De Castro J, Insa A, Collado R, Escudero V, Martínez A, Fernández E, Sullivan I, Arrabal N, Carcedo D, Manzanque A. Economic burden of locoregional and metastatic relapses in resectable ear-



05.1.2 Oncohematologic Diseases Area

- ly-stage non-small cell lung cancer in Spain. *BMC Pulmonary Medicine*. 2023; 23(1):69. DOI:10.1186/s12890-023-02356-0. PMID:36809990. IF:3,100 (Q3/7D). Document type: Article.
- de Velasco G, Alonso T, Rodríguez A, Anguera G, Campayo M, Pinto Á, Ortega EM, Gallardo E, Núñez NF, García I, Reig O, Méndez MJ, Fernández O, Cassinello NV, Torregrosa D, López A, Rosero A, Valiente PG, de España CG, Climent MA, Santasusana MD, Sánchez ÁR, González IC, Afonso R, García del Muro X, Casinello J, Fernández EM, García L, Afonso J, Polo SH, Asensio Ú. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. *Clinical Genitourinary Cancer*. 2023; 21(3):e166-e174. DOI:10.1016/j.clgc.2022.11.021. PMID:36610891. IF:3,200 (Q2/4D). Document type: Article.
 - Escuin D, López L, Bell O, Mora J, García B, Moral A, Clos M, Boronat L, Arqueros C, Barnadas A. Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*. 2023; 24(17):13293. DOI:10.3390/ijms241713293. PMID:37686099. IF:5,600 (Q1/3D). Document type: Article.
 - Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Molina J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Cattrini C, Nogueira L, de Carvalho R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernández M, Bassanelli M, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchenhorn D, Santini D, Manneh R, Bissoni R, Zakopoulou R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Sorgen-toni G, Battelli N, Porta C, Bellmunt J, Santoni M. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. *CANCER IMMUNOLOGY IMMUNOTHERAPY*. 2023; 72(11)DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:5,800 (Q1/3D). Document type: Article.
 - Frezza AM, Stacchiotti S, Chibon F, Coindre JM, Italiano A, Romagnosa C, Bagué S, Dei AP, Braglia L, Palmerini E, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Brunello A, Blay JY, Beveridge RD, Lugowska I, Lesluyes T, Maestro R, Merlo FD, Casali PG, Gronchi A. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-ST5 1001 study. *Cancer Medicine*. 2023; 12(2)DOI:10.1002/cam4.5015. PMID:35848358. IF:4,000 (Q2/4D). Document type: Article.
 - Fumagalli C, Orellana R, Ferre M, Gonzalez A, Catusas L, Vazquez T, Sebio A, López A, Llauger J, Peiro A, Antonescu CR. Expanding the molecular landscape of undifferentiated sarcomas of bone with a novel *EWSR1-SSX3* gene fusion. *GENES CHROMOSOMES & CANCER*. 2023; 63(1)DOI:10.1002/gcc.23215. PMID:38050902. IF:3,700 (Q2/4D). Document type: Article.
 - García JA, Blancas I, Echavarría I, Hinojo C, Margeli M, Moreno F, Pernas S, Cajal TRY, Ribelles N, Bellet M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022). *Clinical & Translational Oncology*. 2023; 25(9)DOI:10.1007/s12094-023-03203-8. PMID:37148499. IF:3,400 (Q3/6D). Document type: Article.
 - García R, González B, Vidal R, Contreras D, Pericay C, Fernández A, Falcó E, González M, Reina JJ, Alonso V, Rodríguez N, Gil M, Santos C, Páez D, Anton B, Aguilar F, Morales P. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. *Clinical & Translational Oncology*. 2023; DOI:10.1007/s12094-023-03309-z. PMID:37651021. IF:3,400 (Q3/6D). Document type: Article.
 - García R, Sullivan I, Arriola E, Insa A, Vidal O, Cruz P, Moran T, Reguart N, Zugazagoitia J, Domine M. SEOM-GECP Clinical guidelines for diagnosis,



05.1.2 Oncohematologic Diseases Area

- treatment and follow-up of small-cell lung cancer (SCLC) (2022). *Clinical & Translational Oncology*. 2023; 25(9)DOI:10.1007/s12094-023-03216-3. PMID:37418123. IF:3,400 (Q3/6D). Document type: Article.
- Giménez A, Sánchez E, de Lope LR, Aguilar A, Sullivan I, Calvo V, Moya I, Viteri S, Cabrera C, Aguado C, Armiger N, Valarezo J, Mayo C, Reguart N, Rosell R, Provencio M, Romero A, Molina MA. Detecting ALK, ROS1, and RET fusions and the MET^{ex14} splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. *Molecular Oncology*. 2023; 17(9)DOI:10.1002/1878-0261.13468. PMID:37243883. IF:6,600 (Q1/3D). Document type: Article.
 - González S, Molina V, Homs R, Martín B, Rodríguez M, González JA, López A, Moral A, Sánchez S. Surgical and oncological results after surgical treatment of patients diagnosed with sarcoma liver metastases. *CIRUGIA ESPAÑOLA*. 2023; 101(2)DOI:10.1016/j.ciresp.2021.11.005. PMID:35901963. IF:1,900 (Q3/6D). Document type: Article.
 - Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. *CLINICAL CANCER RESEARCH*. 2023; 29(17)DOI:10.1158/1078-0432.CCR-22-3146. PMID:37379430. IF:11,500 (Q1/1D). Document type: Article.
 - Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez MJ, Hong S-H, Winkvist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. *Frontiers in Oncology*. 2023; 13:1223282. DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:4,700 (Q2/4D). Document type: Article.
 - Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso T, Eto M, Hutson T, Motzer R, Winkvist E, Maroto P, Keam B, Procopio G, Wong SR, Melichar B, Rolland F, Oya M, Rodríguez K, Saito K, McKenzie J, Porta C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. *European Urology Oncology*. 2023; 6(4) DOI:10.1016/j.euo.2023.01.010. PMID:36720658. IF:8,200 (Q1/1D). Document type: Article.
 - Herbst RS, Wu Y-L, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim S-W, Yu C-J, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, De Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-III A Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. *JOURNAL OF CLINICAL ONCOLOGY*. 2023; 41(10) DOI:10.1200/JCO.22.02186. PMID:36720083. IF:45,300 (Q1/1D). Document type: Article.
 - Isla D, Felip E, Garrido P, Insa A, Majem M, Remon J, Trigo JM, de Castro J. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. *Clinical & Translational Oncology*. 2023; 25(1)DOI:10.1007/s12094-022-02941-5. PMID:36168085. IF:3,400 (Q3/6D). Document type: Article.
 - Isla D, Sánchez A, Casal J, Cobo M, Majem M, Reguart N, Zugazagoitia J, Bernabe R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. *Journal of Clinical Medicine*. 2023; 12(15):5063. DOI:10.3390/jcm12155063. PMID:37568465. IF:3,900 (Q2/4D). Document type: Article.
 - Jimenez P, Foy V, Raby S, Carmona A, Macía L, Arrazubi V, Cacho D, Hernandez San Gil R, Custodio A, Cano JM, Fernández A, Mirallas O, Macias I, Vidal R, Visa L, Limón ML, Pimentel P, Martínez N, Sauri T, Martín M, Mangas



05.1.2 Oncohematologic Diseases Area

M, Gil M, Calvo A, Reguera P, Granja M, Martín A, Hernández C, Cerdá P, Gomez L, García F, Pacheco V, Gutierrez D, Ruiz M, Weaver J, Mansoor W, Gallego J. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. *Therapeutic Advances in Medical Oncology*. 2023; 15:17588359231157641. DOI:10.1177/17588359231157641. PMID:36895850. IF:4,900 (Q2/4D). Document type: Article.

- John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su W-C, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu Y-L, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. *Journal of Thoracic Oncology*. 2023; 18(9) DOI:10.1016/j.jtho.2023.05.015. PMID:37236398. IF:20,400 (Q1/1D). Document type: Article.
- John T, Majem M, Legg D, Goldman J. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. *Targeted Oncology*. 2023; 18(1) DOI:10.1007/s11523-022-00927-5. PMID:36534268. IF:5,400 (Q2/3D). Document type: Editorial Material.
- Kobel M, Kang EY, Weir A, Rambau PF, Lee CH, Nelson GS, Ghatage P, Meagher NS, Riggan MJ, Alsop J, Anglesio MS, Beckmann MW, Bisinotto C, Boisen M, Boros J, Brand AH, Brooks A, Carney ME, Coulson P, Courtney M, Cushing KL, Cybulski C, Deen S, El MA, Elishaev E, Erber R, Fereday S, Fischer A, Gayther SA, Barquin A, Gentry A, Gilks CB, Gronwald H, Grube M, Harnett PR, Harris HR, Hartkopf AD, Hartmann A, Hein A, Hendley J, Hernandez BY, Huang YJ, Jakubowska A, Jimenez M, Jones ME, Kennedy CJ, Kluz T, Koziak JM, Lesnock J, Lester J, Lubinski J, Longacre TA, Lycke M, Mateoiu C, McCauley BM, McGuire V, Ney B, Olawaiye A, Orsulic S, Osorio A, Paz L, Cajal TRY, Rothstein JH, Ruebner M, Schoemaker MJ, Shah MT, Sharma R, Sherman ME, Shvetsov YB, Singh N, Steed H, Storr SJ, Talhouk A, Traficante N, Wang C, Whittemore AS, Widschwendter M, Wilkens LR, Winham SJ, Benitez J, Berchuck A, Bowtell DD, dos FJC, Campbell I, Cook LS, DeFazio A, Doherty JA, Fasching PA, Fortner RT, García MJ, Goodman MT, Goode EL, Gronwald J, Huntsman DG, Karlan BY, Kelemen LE, Kommoss S, Le ND, Martin SG, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sieh W, Staebler A, Sundfeldt K, Swerdlow AJ, Ramus SJ, Brenton JD, AOCs GRP. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology Clinical Research*. 2023; 9(3) DOI:10.1002/cjp.2.311. PMID:36948887. IF:4,100 (Q2/3D). Document type: Article.
- López A, González P, Sanz J, Prieto JD, Trias I, Luque RJ, Semidey ME, Maroto P, Algaba F. Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP. *Revista Española De Patología*. 2023; 56(4) DOI:10.1016/j.patol.2023.05.001. PMID:37879823. Document type: Review.
- Lozano R, Castro E, FL, Thorne H, Ramirez M, Aragon IM, Cendon Y, Gutierrez A, Salles DC, Romero N, Lorente D, Gonzalez P, Calatrava A, Alonso C, Anido U, Arevalo S, Balmana J, Chirivella I, Juan MJ, Llorca G, Cajal TRY, Almagro E, Alameda D, López PP, Herrera B, Mateo J, Pritchard CC, Antonarakis ES, Lotan TL, Rubio J, Sandhu S, Olmos D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. *EUROPEAN JOURNAL OF CANCER*. 2023; 185 DOI:10.1016/j.ejca.2023.02.022. PMID:36972661. IF:8,400 (Q1/2D). Document type: Article.
- Macaulay VM, Lord S, Hussain S, Maroto JP, Jones RH, Climent MÁ, Cook N, Lin CC, Wang SS, Bianchini D, Bailey M, Schlieker L, Bogenrieder T, de Bono J. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. *BRITISH JOURNAL OF CANCER*. 2023; 129(6) DOI:10.1038/s41416-023-02380-1. PMID:37537253. IF:8,800 (Q1/2D). Document type: Article.
- Manzano JL, Martin J, Fernández LA, Benítez G, Medina J, Quindós M, García A, Fernández O, Simo RV, Majem M, Bellido L, Ayala de Miguel P,



05.1.2 Oncohematologic Diseases Area

- Campos B, Espinosa E, Macías JA, Gil I, Lorente D, Rodríguez A, Perez VN, López R, Gramaje MG, Puértolas T, Rodríguez JF, Espasa L, Be-laustegui G, Cerezuela P. Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study. *MELANOMA RESEARCH*. 2023; 33(5)DOI:10.1097/CMR.0000000000000888. PMID:36988401. IF:2,200 (Q3/7D). Document type: Article.
- Martin J, Martinez J, Moura DS, Redondo A, Gutierrez A, López A, Martinez J, Sevilla I, Díaz R, Solis MP, Carnero A, Perez M, Marcilla D, García J, Romero P, Fernández J, López D, Arribas I, Hindi N. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. *Signal Transduction and Targeted Therapy*. 2023; 8(1):405. DOI:10.1038/s41392-023-01661-8. IF:39,300 (Q1/1D). Document type: Article.
 - Martinez DAS, Quilez A, Jimenez P, Sesma A, Tarazona N, Pacheco V, Obispo B, Paez D, Quintanar T, Sánchez M, Montes AF, Felip E, Rodríguez A, Elez E. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section. *Clinical & Translational Oncology*. 2023; 25(3) DOI:10.1007/s12094-022-02989-3. PMID:36418642. IF:3,400 (Q3/6D). Document type: Article.
 - Martinez N, Vilarino N, Alameda F, Mojal S, Arumi M, Carrato C, Aldecoa I, Ribalta T, Vidal N, Belloso-Ilo B, Menéndez S, Del Barco S, Gallego O, Pineda E, López R, Hernandez A, Mesia C, Esteve A, de la Iglesia N, Balana C, Martinez M, Navarro P. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. *Cells*. 2023; 12(6):843. DOI:10.3390/cells12060843. PMID:36980184. IF:6,000 (Q2/4D). Document type: Article.
 - Mayayo C, de Heredia ML, Prat E, Gonzalez L, Guarch ME, Vilches C, Munoz L, Asensi MA, Serra C, Llebaria A, Casado M, Artuch R, Garrabou G, García PM, Pallardo FV, Nunes V. The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. *Redox Biology*. 2023; 64:102801. DOI:10.1016/j.redox.2023.102801. PMID:37418888. IF:11,400 (Q1/1D). Document type: Article.
 - Nadal E, Oré M, Remon J, Bernabé R, Covela M, de Castro J, Massutí B, Guillot M, Majem M, Maestu I, Morilla I, Gironés R. Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer. *Clinical & Translational Oncology*. 2023; 25(11)DOI:10.1007/s12094-023-03286-3. PMID:37566345. IF:3,400 (Q3/6D). Document type: Article.
 - Nadal E, Rodríguez D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GEC17/05). *JOURNAL OF CLINICAL ONCOLOGY*. 2023; 41(28)DOI:10.1200/JCO.22.02561. PMID:37603816. IF:45,300 (Q1/1D). Document type: Article.
 - O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto JP, Ferrario C, Carret A-S, Yu Y, Guseva M, Homet B, Rosenberg JE. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. *JOURNAL OF CLINICAL ONCOLOGY*. 2023; 41(25)DOI:10.1200/JCO.22.02887. PMID:37369081. IF:45,300 (Q1/1D). Document type: Article.
 - Peters S, Letovanec I, Mauer M, Dafni U, Eje-depang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N, Tarruella MM, Casas J, Tsourtis Z, Marti N, Kammler R, Danson S, O'Brien M, Stahel RA. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOR randomized clinical trial. *LUNG CANCER*. 2023; 175DOI:10.1016/j.lungcan.2022.12.004. PMID:36535121. IF:5,300 (Q2/3D). Document type: Article.
 - Pilcher L, Pahlke S, Urquhart O, O'Brien KK, Dhar V, Fontana M, Gonzalez C, Keels MA, Mascarenhas AK, Nascimento MM, Platt JA, Sabino GJ,



05.1.2 Oncohematologic Diseases Area

- Slayton RL, Tinanoff N, Young DA, Zero DT, Tampi MP, Purnell D, Salazar J, Megremis S, Bienek D, Carrasco A. Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs. *JOURNAL OF THE AMERICAN DENTAL ASSOCIATION*. 2023; 154(2) DOI:10.1016/j.adaj.2022.09.012. PMID:36610925. IF:3,900 (Q1/2D). Document type: Article.
- Provencio M, Estival A, Franco F, López G, Saigí M, Arasanz H, Diz P, Carcereny E, García J, Aguado C, Mosquera J, Iruarizaga E, Majem M, Bosch J, Mielgo X, Guirado M, Juan Ó, Blasco A, Lucía C, Del Barrio A, De Portugal T, López A, Serrano G, Campos B, Rubio J, Catot S, Esteban B, Martí JL, del Barco E, Calvo V. Immunogenicity of COVID-19 vaccines in lung cancer patients. *LUNG CANCER*. 2023; 184:107323. DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:5,300 (Q2/3D). Document type: Article.
 - Provencio M, Ortega AL, Coves J, Calvo V, Marsé R, Dómine M, Guirado M, Carcereny E, Fernández N, Álvarez R, Blanco R, León L, Sánchez JM, Sullivan IG, Cobo M, Sánchez A, Massuti B, Sierra B, Martínez C, Serna R, Romero A, Cruz A. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. *JAMA Oncology*. 2023; 9(3)DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:28,400 (Q1/1D). Document type: Article.
 - Remon J, Besse B, Aix SP, Callejo A, Al K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazieres J, Curcio H, Wasag B, Pretzenbacher Y, Fournier B, Dingemans A, Dziadziuszko R. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. *ANNALS OF ONCOLOGY*. 2023; 34(5)DOI:10.1016/j.annonc.2023.02.012. PMID:36863484. IF:50,500 (Q1/1D). Document type: Article.
 - Rodríguez A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios A, Cano L, Alonso J, Martinez G, Galtés S, Taus A, Martinez M, Juanpere N, Juan O, Bellmunt J. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. *BRITISH JOURNAL OF CANCER*. 2023; 128(1)DOI:10.1038/s41416-022-01991-4. PMID:36289372. IF:8,800 (Q1/2D). Document type: Article.
 - Roldan JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez A, Monteagudo M, Mellid S, Leandro LJ, Montero C, Cascon A, Roncador G, Coloma J, Robledo M, Rodríguez C. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. *INTERNATIONAL JOURNAL OF CANCER*. 2023; 153(6) DOI:10.1002/ijc.34575. PMID:37260183. IF:6,400 (Q1/3D). Document type: Article.
 - Rueda A, Mendoza JI, Alba L, Parladé E, Voltà E, Paez D, Aviño A, Eritja R, Vázquez E, Villaverde A, Mangues R, Unzueta U. Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs). *Science China-Materials*. 2023; 66(10)DOI:10.1007/s40843-023-2571-6. IF:8,100 (Q1/3D). Document type: Article.
 - Salazar J, Bracchiglione J, Savall O, Antequera A, Bottaro D, Gutierrez M, Martinez S, Pericay C, Tibau A, Bonfill X, Appropriateness SYSTT. Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review. *BMC CANCER*. 2023; 23(1):748. DOI:10.1186/s12885-023-11207-4. PMID:37573294. IF:3,800 (Q2/5D). Document type: Review.
 - Sánchez A, Cajal TRY, Pineda M, Aguirre E, Grana B, Chirivella I, Balmana J, Brunet J, SEOM Hereditary Canc Working GRP, AEGH Hereditary Canc C. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). *Clinical & Translational Oncology*. 2023; 25(9)DOI:10.1007/s12094-023-03202-9. PMID:37133731. IF:3,400 (Q3/6D). Document type: Article.
 - Sanfilippo R, Hindi N, Jurado JC, Blay JY, López A, Italiano A, Alvarez R, Gutierrez A, Rincon I, Sangalli C, Aguiar JLP, Romero J, Morosi C, Sunyach MP, Fabbri C, Romagosa C, Ranchere D, Dei AP, Casali PG, Martin J, Gronchi A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A



05.1.2 Oncohematologic Diseases Area

- Nonrandomized Clinical Trial. *JAMA Oncology*. 2023; 9(5)DOI:10.1001/jamaoncol.2023.0056. PMID:36995731. IF:28,400 (Q1/1D). Document type: Article.
- Segura PP, Quintela NV, García MM, Berron SD, Sarrío RG, Gomez JG, Castano AG, Martín LMN, Rubio OG, Losada EP. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). *Clinical & Translational Oncology*. 2023; 25(9)DOI:10.1007/s12094-023-03245-y. PMID:37540408. IF:3,400 (Q3/6D). Document type: Article.
 - Serrano C, Álvarez R, Carrasco JA, Marquina G, Martínez J, Martínez V, Sala MÁ, Sebio A, Sevilla I, Martín J. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). *Clinical & Translational Oncology*. 2023; 25(9)DOI:10.1007/s12094-023-03177-7. PMID:37129716. IF:3,400 (Q3/6D). Document type: Article.
 - Tibau A, Martínez MT, Ramos M, De La Cruz L, Santaballa A, O'Connor M, Martínez N, Moreno F, Fernández I, Virizuela JA, Alarcón J, de La Haba J, Sánchez P, Albarca CR, Bueno C, Kelly C, Casas M, Bezares S, Rosell L, Albanell J. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. *Therapeutic Advances in Medical Oncology*. 2023; 15:17588359221148921. DOI:10.1177/17588359221148921. PMID:36743520. IF:4,900 (Q2/4D). Document type: Article.
 - Trilla L, Gámez A, Prado G, López R, Soriano V, Garicano F, Lecumberri MJ, Rodríguez de la Borbolla M, Majem M, Pérez E, González M, Oramas J, Magdaleno A, Fra J, Martín A, Corral M, Puértolas T, Ramos R, Dittmann A, Nanni P, Fresno JÁ, Espinosa E. Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma. *Cancers*. 2023; 15(17):4407. DOI:10.3390/cancers15174407. PMID:37686682. IF:5,200 (Q2/3D). Document type: Article.
 - Trilla L, Gámez A, Prado G, López R, Zapater A, López E, Lumbreras MI, Soriano V, Garicano F, Lecumberri MJ, de la Borbolla MR, Majem M, Pérez E, González M, Oramas J, Magdaleno A, Fra J, Martín A, Corral M, Puértolas T, Ramos R, Ramos R, Vara J, Espinosa E. Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma. *INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES*. 2023; 24(1):801. DOI:10.3390/ijms24010801. PMID:36614248. IF:5,600 (Q1/3D). Document type: Article.
 - Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, De Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL, ADAURA I. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. *NEW ENGLAND JOURNAL OF MEDICINE*. 2023; 389(2)DOI:10.1056/NEJMoa2304594. PMID:37272535. IF:158,500 (Q1/1D). Document type: Article.
 - Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, Chen A, van der Gronde T, He J. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. *Clinical Lung Cancer*. 2023; 24(4) DOI:10.1016/j.clcc.2023.02.002. PMID:36872181. IF:3,600 (Q2/5D). Document type: Article.
 - Valcarcel S, Gallego J, Jimenez P, Diez M, de Castro EM, Hernandez R, Arrazubi V, Custodio A, Cano JM, Montes AF, Macias I, Visa L, Calvo A, Tocino RV, Lago NM, Limon ML, Granja M, Gil M, Pimentel P, Macia L, Perez CH, Mangas M, Carnicero AM, Cerda P, Gonzalez LG, Navalon FG, Rambla MDM, Richard MM, Carmona A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. *JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY*. 2023; 149(7)DOI:10.1007/s00432-022-04294-6. PMID:36042046. IF:3,600 (Q2/5D). Document type: Article.
 - Vazquez JC, Antolin S, Ruiz M, Servitja S, Alba E, Barnadas A, Lluch A, Martín M, Rodríguez A, Sola I, Bonfill X, Urrutia G, Sánchez P. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a



05.1.2 Oncohematologic Diseases Area

systematic review and meta-analysis. *Clinical & Translational Oncology*. 2023; 25(4)DOI:10.1007/s12094-022-02998-2. PMID:36417083. IF:3,400 (Q3/6D). Document type: Review.

- Vazquez JC, Pinero A, de Castro FJ, Lluch A, Martín M, Barnadas A, Alba E, Rodríguez A, Rojo F, Gimenez J, Sola I, Quintana MJ, Bonfill X, Urrutia G, Sánchez P. The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review. *Clinical & Translational Oncology*. 2023; 25(2)DOI:10.1007/s12094-022-02953-1. PMID:36153763. IF:3,400 (Q3/6D). Document type: Review.
- Vidal J, Fernández MC, Casadevall D, García P, Páez D, Guix M, Alonso V, Cano MT, Santos C, Durán G, Elez E, Manzano JL, García R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. *CLINICAL CANCER RESEARCH*. 2023; 29(2)DOI:10.1158/1078-0432.CCR-22-1696. PMID:36074154. IF:11,500 (Q1/1D). Document type: Article.
- Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, Chen K-N, Dooks C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. *NEW ENGLAND JOURNAL OF MEDICINE*. 2023; 389(6)DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:158,500 (Q1/1D). Document type: Article.